BridgeBio Pharma, Inc.
DE ˙ MUN ˙ US10806X1028
56,19 € ↓ -1,02 (-1,78%)
2026-06-01
AKTIENPREIS
SecurityDE:2CL / BridgeBio Pharma, Inc.
InstitutionUBS Group AG
Latest Disclosed Ownership2,026,821 shares
Latest Disclosed Value $ 150,511,728
UBS Group AG ownership in 2CL / BridgeBio Pharma, Inc.

On May 5, 2026 - UBS Group AG filed a 13F-HR form disclosing ownership of 2,026,821 shares of BridgeBio Pharma, Inc. (DE:2CL) valued at $127,365,432 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 29, 2026 disclosing 1,875,665 shares of BridgeBio Pharma, Inc.. This represents a change in shares of 8.06% during the quarter. The current value of the position is $113,887,072 USD.

UBS Group AG has a history of taking positions in derivatives of the underlying security (2CL) in the form of stock options. The firm currently holds call options representing 3,863,500 of underlying shares valued at $286,903,510 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

DE:2CL / BridgeBio Pharma, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-05 2026-03-31 13F BRIDGEBIO PHARMA COM 10806X102 2,026,821 151,156 8.06 150,512 4.91 0.0042
2026-01-29 2025-12-31 13F BRIDGEBIO PHARMA COM 10806X102 1,875,665 -710,757 -27.48 143,470 6.80 0.0042
2025-11-13 2025-09-30 13F BRIDGEBIO PHARMA COM 10806X102 2,586,422 -226,077 -8.04 134,339 10.62 0.0210
2025-08-14 2025-06-30 13F BRIDGEBIO PHARMA COM 10806X102 2,812,499 613,985 27.93 121,444 59.79 0.0210
2025-05-13 2025-03-31 13F BRIDGEBIO PHARMA COM 10806X102 2,198,514 358,659 19.49 76,003 50.54 0.0140
2025-02-14 2024-12-31 13F BRIDGEBIO PHARMA COM 10806X102 1,839,855 753,062 69.29 50,486 82.46 0.0093
2024-11-14 2024-09-30 13F BRIDGEBIO PHARMA COM 10806X102 1,086,793 -5,521 -0.51 27,670 0.00 0.0060
2024-08-14 2024-06-30 13F BRIDGEBIO PHARMA COM 10806X102 1,092,314 -7,232 -0.66 27,668 -18.62 0.0068
2024-05-13 2024-03-31 13F BRIDGEBIO PHARMA COM 10806X102 1,099,546 114,036 11.57 33,998 -14.55 0.0085
2024-02-09 2023-12-31 13F BRIDGEBIO PHARMA COM 10806X102 985,510 832,940 545.94 39,785 888.94 0.0119
2023-11-09 2023-09-30 13F BRIDGEBIO PHARMA COM 10806X102 152,570 -10,011 -6.16 4,023 43.88 0.0014
2023-08-11 2023-06-30 13F BRIDGEBIO PHARMA COM 10806X102 162,581 77,843 91.86 2,796 99.15 0.0009
2023-05-12 2023-03-31 13F BRIDGEBIO PHARMA COM 10806X102 84,738 -275,140 -76.45 1,405 -48.80 0.0005
2023-02-08 2022-12-31 13F BRIDGEBIO PHARMA COM 10806X102 359,878 351,065 3,983.49 2,742 3,015.91 0.0010
2022-11-10 2022-09-30 13F BRIDGEBIO PHARMA COM 10806X102 8,813 -212,264 -96.01 88 -95.62 0.0000
2022-08-10 2022-06-30 13F BRIDGEBIO PHARMA COM 10806X102 221,077 -220,963 -49.99 2,008 -55.25 0.0008
2022-05-16 2022-03-31 13F BRIDGEBIO PHARMA COM 10806X102 442,040 377,753 587.60 4,487 318.17 0.0015
2022-02-14 2021-12-31 13F BRIDGEBIO PHARMA COM 10806X102 64,287 -48,438 -42.97 1,073 -79.69 0.0003
2021-11-15 2021-09-30 13F BRIDGEBIO PHARMA COM 10806X102 112,725 90,850 415.31 5,283 296.32 0.0017
2021-08-13 2021-06-30 13F BRIDGEBIO PHARMA COM 10806X102 21,875 8,534 63.97 1,333 62.17 0.0004
2021-05-12 2021-03-31 13F BRIDGEBIO PHARMA COM 10806X102 13,341 -5,777 -30.22 822 -39.51 0.0003
2021-02-11 2020-12-31 13F BRIDGEBIO PHARMA COM 10806X102 19,118 823 4.50 1,359 98.10 0.0005
2020-11-12 2020-09-30 13F BRIDGEBIO PHARMA COM 10806X102 18,295 -1,049 -5.42 686 8.72 0.0003
2020-07-31 2020-06-30 13F BRIDGEBIO PHARMA COM 10806X102 19,344 3,424 21.51 631 36.58 0.0003
2020-05-01 2020-03-31 13F BRIDGEBIO PHARMA COM 10806X102 15,920 -2,121 -11.76 462 -26.90 0.0002
2020-02-14 2019-12-31 13F BRIDGEBIO PHARMA COM 10806X102 18,041 -15,658 -46.46 632 -12.59 0.0002
2019-11-14 2019-09-30 13F BRIDGEBIO PHARMA COM 10806X102 33,699 33,099 5,516.50 723 4,418.75 0.0003
2019-08-14 2019-06-30 13F BRIDGEBIO PHARMA COM 10806X102 600 600 16 0.0000
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-05 2026-03-31 13F BRIDGEBIO PHARMA COM Call 3,863,500 0.00 286,904 -2.92 n/a n/a n/a
2026-01-29 2025-12-31 13F BRIDGEBIO PHARMA COM Call 3,863,500 0.00 295,519 47.27 n/a n/a n/a
2025-11-13 2025-09-30 13F BRIDGEBIO PHARMA COM Call 3,863,500 0.00 200,670 20.29 n/a n/a n/a
2025-08-14 2025-06-30 13F BRIDGEBIO PHARMA COM Call 3,863,500 -0.58 166,826 24.18 n/a n/a n/a
2025-05-13 2025-03-31 13F BRIDGEBIO PHARMA COM Call 3,886,200 -2.89 134,346 22.34 n/a n/a n/a
2025-02-14 2024-12-31 13F BRIDGEBIO PHARMA COM Call 4,001,800 -2.62 109,809 4.96 n/a n/a n/a
2024-11-14 2024-09-30 13F BRIDGEBIO PHARMA COM Call 4,109,300 6.36 104,623 6.91 n/a n/a n/a
2024-08-14 2024-06-30 13F BRIDGEBIO PHARMA COM Call 3,863,500 0.00 97,862 -18.08 n/a n/a n/a
2024-05-13 2024-03-31 13F BRIDGEBIO PHARMA COM Call 3,863,500 119,459 n/a n/a n/a
2023-11-09 2023-09-30 13F BRIDGEBIO PHARMA COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2023-08-11 2023-06-30 13F BRIDGEBIO PHARMA COM Call 12,100 208 n/a n/a n/a
2022-05-16 2022-03-31 13F BRIDGEBIO PHARMA COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2022-02-14 2021-12-31 13F BRIDGEBIO PHARMA COM Call 4,900 82 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2022-05-16 2022-03-31 13F BRIDGEBIO PHARMA COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2022-02-14 2021-12-31 13F BRIDGEBIO PHARMA COM Put 4,200 70 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.